Abstract:The data on pathological response and survival outcomes after neoadjuvant chemotherapy (NACT) in human epidermal growth factor receptor-2 (HER2)-low breast cancer (BC) is limited. We retrospectively retrieved clinicopathological data of 819 HER2-negative BC patients who received NACT between 2010 and 2020 from Shanghai Jiaotong University Breast Cancer Database. The results revealed that HER2-low expression was significantly associated with breast pathological complete response (pCR) in HER2-negative BC, but not with pCR or survival. Furthermore, estrogen receptor expression had a significantly prognostic impact on HER2-low BC. Background: Data on the pathological responses and survival outcomes after neoadjuvant chemotherapy (NACT) in human epidermal growth factor receptor-2 (HER2)-low breast cancer (BC) are lacking. This study aims to investigate this topic in the real world. Methods: Clinicopathological data from 819 HER2-negative BC patients who underwent NACT between 2010 and 2020 were retrospectively retrieved from the Shanghai Jiaotong University Breast Cancer Database. These patients were categorized into HER2-low and HER2-0 groups. Logistic analyses were conducted to identify predictors of complete pathological response (pCR) and breast pCR. Cox regression analyses were conducted to assess the factors associated with disease-free survival (DFS) and overall survival (OS). Kaplan-Meier (K-M) curves were generated to compare DFS and OS between HER2-low BC and HER2-0 BC. Results: Of the 819 BC patients, 669 (81.7%) had HER2-low tumors, and 150 (18.3%) had HER2-0 tumors. HER2-low BC had a significantly higher ratio of ER >= 10%, PR >= 20%, and Ki67 >= 15% than HER2-0 BC. A significantly higher breast pCR rate was observed in HER2-low BC than in HER2-0 BC (13.6% and 7.3%, respectively, P = .036). Age, HER2 status (low or 0), Ki67, and surgery options were associated with breast pCR in HER2-negative BC. In HER2-low BC, the pCR rate of ER >_ 10% BC was significantly lower than that of ER < 10% BC, but the DFS and OS of ER 10% BC were significantly higher. The K-M curve showed no significant differences in DFS or OS between HER2-low and HER2-0 BC. Cox regression revealed that ER expression and histological grade (III vs. I ' II) were significantly associated with survival in HER2-low BC. Conclusions: In this real-world data (RWD) study, a significantly higher breast pCR rate was found in HER2-low BC than in HER2-0 BC, although there was no significant difference in survival. Moreover, ER expression had a significant prognostic impact on HER2-low BC. Clinical Breast Cancer, Vol. 24, No. 5, 463-472

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study

HER2 Protein Expression Level is Positively Associated with the Efficacy of Neoadjuvant Systemic Therapy in HER2-positive Breast Cancer

Efficacy and prognosis of neoadjuvant chemotherapy in HER2 low-expressing breast cancer: a retrospective single-center study

Real-world Data on Pathological Response and Survival Outcomes after Neoadjuvant Chemotherapy in HER2-low Breast Cancer Patients

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Neoadjuvant Chemotherapy Efficacy and Prognosis in HER2-low and HER2-zero Breast Cancer Patients by HR Status: a Retrospective Study in China

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study

Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Before Surgery: A Retrospective Analysis

[Efficacy of neoadjuvant therapy on HER2-positive breast cancer: a clinicopathological analysis].

Analysis of Factors Influencing the Efficacy of NAC and Prognosis Between HER2-zero and HER2-low HR Negative Breast Cancer

Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis

Pathological Complete Response Rate and Clinical Outcome after Neoadjuvant Therapy of HER2-low Breast Cancer: A National Cancer Database Analysis.

Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-low-positive and HER2-zero Breast Cancer

Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Chemotherapy Between HER2-low and HER2-zero Breast Cancer

Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer

Estrogen Receptor Expression: Possible Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.

Impact of HER2-low Status for Patients with Early-Stage Breast Cancer and Non-Pcr after Neoadjuvant Chemotherapy: A National Cancer Database Analysis

Efficacy Analysis of Neoadjuvant Chemotherapy with or Without Anthracyclines in Female Patients with HER2-positive Breast Cancer in China: a Nationwide, Multicenter, 10-Year Retrospective Study (Csbrs-012)